B. Chastek, S. Korrer, and S. P. Nagar, Economic burden of illness among patients with severe asthma in a managed care setting, J Manag Care Spec Pharm, vol.22, pp.848-861, 2016.

D. M. Lang, Severe asthma: epidemiology, burden of illness, and heterogeneity, Allergy Asthma Proc, vol.36, pp.418-424, 2015.

M. Kerkhof, T. N. Tran, and J. B. Soriano, Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population, Thorax, vol.73, pp.116-124, 2018.

C. Nunes, A. M. Pereira, and M. Morais-almeida, Asthma costs and social impact, Asthma Res Pract, vol.3, p.1, 2017.

,

J. I. Ivanova, R. Bergman, and H. G. Birnbaum, Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma, J Allergy Clin Immunol, vol.129, pp.1229-1235, 2012.

, CINQAIR® (reslizumab) label, Teva Pharmaceutical Industries Ltd, 2016.

L. Glaxosmithkline, NUCALA® (mepolizumab) label. www.accessdata.fda.gov/drugsatfda_docs/label/2015/ 125526Orig1s000Lbl.pdf. Date last updated, Date last accessed, 2015.

, FASENRA? (benralizumab) label, AstraZeneca, 2018.

E. R. Bleecker, J. M. Fitzgerald, and P. Chanez, Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet, vol.388, pp.2115-2127, 2016.

M. Castro, J. Zangrilli, and M. E. Wechsler, Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials, Lancet Respir Med, vol.3, pp.355-366, 2015.

J. M. Fitzgerald, E. R. Bleecker, and P. Nair, Benralizumab, an anti-interleukin-5 receptor ? monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, vol.388, pp.2128-2141, 2016.

H. Ortega, M. C. Liu, and I. D. Pavord, Mepolizumab treatment in patients with severe eosinophilic asthma, N Engl J Med, vol.371, pp.1198-1207, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01785638

I. D. Pavord, S. Korn, and P. Howarth, Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet, vol.380, pp.651-659, 2012.

S. M. Cockle, G. Stynes, and N. B. Gunsoy, Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison, Respir Med, vol.123, pp.140-148, 2017.

Y. Cabon, N. Molinari, and G. Marin, Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials, Clin Exp Allergy, vol.47, pp.129-138, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01798677

T. Casale, L. Mesana, and M. Pacou, Reslizumab versus benralizumab in patients with inadequately controlled asthma: a Bayesian network meta-analysis, Eur Respir J, vol.50, 2017.

J. E. Signorovitch, V. Sikirica, and M. H. Erder, Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research, Value Health, vol.15, pp.940-947, 2012.

J. Pocoski, N. Li, and R. Ayyagari, Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 versus two recombinant factor VIII for the prophylactic treatment of severe hemophilia A, J Blood Med, vol.7, pp.129-137, 2016.

J. E. Signorovitch, E. Q. Wu, and A. P. Yu, Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept, Pharmacoeconomics, vol.28, pp.935-945, 2010.

S. Van-sanden, T. Ito, and J. Diels, Comparative efficacy of daratumumab monotherapy and pomalidomide plus low-dose dexamethasone in the treatment of multiple myeloma: a matching adjusted indirect comparison, Oncologist, vol.23, pp.279-287, 2018.

D. M. Phillippo, A. E. Ades, and S. Dias, NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE, 2016.

B. Hutton, G. Salanti, and D. M. Caldwell, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations, Ann Intern Med, vol.162, pp.777-784, 2015.

. Nice-sta, Specification for manufacturer/sponsor submission of evidence, 2012.

H. C. Bucher, G. H. Guyatt, and L. E. Griffith, The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials, J Clin Epidemiol, vol.50, pp.683-691, 1997.

G. L. Chupp, E. S. Bradford, and F. C. Albers, Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebocontrolled, parallel-group, multicentre, phase 3b trial, Lancet Respir Med, vol.5, pp.390-400, 2017.

H. A. Farne, A. Wilson, and C. Powell, Anti-IL5 therapies for asthma, Cochrane Database Syst Rev, vol.9, p.10834, 2017.

,